Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Urea + 5-fluorouracil** is a topical combination drug formulation, primarily used for the treatment of actinic keratosis and resistant or difficult-to-treat hyperkeratotic skin lesions. 5-fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase, thereby blocking DNA synthesis and leading to apoptosis in aberrant keratinocytes[1]. Urea acts as a keratolytic agent, enhancing the penetration of 5-fluorouracil into thickened, hyperkeratotic lesions and softening the stratum corneum. The combination is predominantly indicated in dermatology, especially in cases where monotherapy with 5-fluorouracil is less effective due to the physical barrier of hyperkeratosis. It is not systemically absorbed in significant amounts when used as a topical formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on urea + 5-fluorouracil.